• Publications
  • Influence
The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation
Differences in binding to viral peptide antigens by HLA may be the major factors underlying genetic differences between HIV controllers and progressors, and genome-wide association results implicate the nature of the HLA–viral peptide interaction as the major factor modulating durable control of HIV infection.
Randomized controlled trial of a personalized cellular phone reminder system to enhance adherence to antiretroviral therapy.
Over 6 weeks adherence increased and remained significantly higher in the ARemind group using multiple measures of adherence; a larger and longer prospective study is needed to confirm these findings and to better understand optimal reminder messages and user fatigue.
Optimal Recall Period and Response Task for Self-Reported HIV Medication Adherence
It is concluded that 1-month recall periods may be more accurate than 3- or 7-day periods, and that items that ask respondents to rate their adherence may beMore accurate than those that ask about frequencies or percents.
A Practical Guide to Vaccinating the Inflammatory Bowel Disease Patient
The increasing use of corticosteroids, immune modulators, and biologics as a mainstay of therapy in certain Crohn's disease and ulcerative colitis patients have placed these inflammatory bowel
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.
In HIV-1-infected, treatment-experienced patients, vicriviroc demonstrated potent virologic suppression through 24 weeks and the relationship of vicrivIROc to malignancy is uncertain.
Atazanavir is an inhibitor and inducer of P-gp as well as a potent inhibitor of CYP3A in vitro, suggesting a potential for atazanvir to cause drug-drug interactions in vivo.
Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384.
The results support current guidelines to start ART at a threshold of 350 cells/mm(3) and suggest that there may be immunological benefits associated with initiating therapy at even higher CD4(+) cell counts.
Surfactant protein D binds to human immunodeficiency virus (HIV) envelope protein gp120 and inhibits HIV replication.
It is demonstrated that surfactant protein D (SP-D) binds to gp120 and inhibits HIV infectivity at significantly lower concentrations than MBL and a chimeric protein containing the N-terminal and collagen domains of SP-D linked to the neck and carbohydrate-recognition domains of MBL had greater ability to bind to gp 120 and inhibit virus replication.
The effect of protease inhibitors on weight and body composition in HIV‐infected patients
PI therapy of HIV infection is associated with weight gain and improvement in quality of life indices, and patients who responded to PI therapy with decreased viral load had significantly greater weight gain per month than non-responders.
Impaired function of circulating HIV-specific CD8(+) T cells in chronic human immunodeficiency virus infection.
It is suggested that a significant proportion of HIV-specific CD8 T cells may be functionally compromised in vivo and that some function can be restored by exposure to IL-2.